2 minute read - 31st January 2025
Upperton Pharma completes build of new £7m manufacturing facility
Upperton Pharma Solutions, a specialist contract development and manufacturing firm, has completed the build of its new sterile manufacturing facility in Nottingham.
The 7,000 sq ft facility will support the manufacturing of aseptic and terminally sterilised small-volume liquids and powders for parenteral, nasal, and pulmonary delivery. The new build is in addition to Trent Gateway, the company’s existing 50,000 sq ft site.
The new facility can support formulation development, clinical manufacture, and analytical testing. It can handle batch sizes of up to 2,000 vials, pre-filled syringes, and pre-filled cartridges for liquid formulations and pre-sterilised powders.
The expansion is a natural progression for Upperton, which already develops and manufactures small molecule and biological, non-sterile, oral, nasal, and pulmonary dosage forms from early development to late-stage clinical manufacture for global biotech and pharmaceutical companies.
Never miss the latest manufacturing news by signing up to our newsletter here
Upperton Pharma Solutions has completed the build of its new £7m sterile manufacturing facility in Nottingham / Picture: Upperton Pharma Solutions
Nikki Whitfield, chief executive officer at Upperton, said: “We are delighted to complete the build of our sterile facility. The combined experience of our leadership team in sterile facility builds and subsequent operations ensures that we are ideally placed as a CDMO partner of choice for small to mid-sized biotech and pharma looking to get into the clinic quickly with fast access to sterile manufacturing services.”
The sterile facility will feature two cleanrooms with advanced VHP isolation technology and carry out GMP manufacturing of sterile drug products making use of existing full-service formulation development and quality control laboratories.
Jon Austwick, director of quality & compliance of Upperton, added: “This expansion illustrates our continued investment in our capabilities to support drug developers to scale and accelerate the path to delivering safe and effective medicines to patients. The facility has been built with the highest level of quality and is a testament to our internal teams and build vendor who have worked tirelessly over the past 12 months to bring our vision to life.”
This investment in sterile drug product manufacturing enhances Upperton’s existing service offering, which provides formulation development across a broad range of dosage forms, clinical trial supply, and late-stage manufacturing for non-sterile dosage forms for small molecules and biologics.
While the facility’s commissioning and the installation and validation of new equipment continue, Upperton will utilise existing expertise within its research and development and analytical teams to support the pre-formulation and stability studies for early proof-of-concept products for parenteral, nasal, and pulmonary delivery.
